Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #363776 on Anavex Life Sciences Corp (AVXL)
plexrec
06/19/22 7:34 AM
#363789 RE: georgejjl #363776
nidan7500
06/19/22 9:05 AM
#363798 RE: georgejjl #363776
Wednesday 22 June 2022, Christopher Missling Company: Anavex Life Sciences Job title: President & Chief Executive Officer Seminars: Characterizing Rare Disease Biology in Clinical Studies to Observe Drug Effects in Patient Sub-Populations 11:00 am Understanding the relevance of Whole Exome Sequencing (WES) and mRNA-seq analyses Using unsupervised computerized AI analysis to assess large data Correlating genomic analysis with extensive clinical data outcomes and endpoint scales Details: Understanding the relevance of Whole Exome Sequencing (WES) and mRNA-seq analyses Using unsupervised computerized AI analysis to assess large data Correlating genomic analysis with extensive clinical data outcomes and endpoint scales Day: Day One https://rare-genetic-neurodegenerative-development.com/speaker/christopher-missling-2/ Good luck and GOD bless,